The Companies announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
The Company today announced that it has appointed Irvine O. Hockaday, Jr. to its Board of Directors where he will also serve on the Nominating and Corporate Governance Committee.
Start-Ups Work on Biotech Drugs for Pets, by Andrew Pollack, was a feature article in The New York Times online August 2, 2014.
The Company announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the treatment of canine osteosarcoma and other cancers.
Denali, a therapy dog, inspires patients in hospitals, but is also an inspiration himself.
The Company announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors.
The Company will participate in two upcoming investor conferences, including the JMP Securities Healthcare Conference and Guggenheim Animal Health Day.
The Company announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.
Attendees at ACVIM Forum learned about the Aratana philosophy and got a preview to some of the exciting, innovative products that are in the Aratana pipeline for development.
The Compan announced it has entered into an exclusive license agreement with Vet-Stem, Inc., for its novel, allogeneic stem cell therapy technology.
The Company announced findings from the company’s ongoing safety and clinical programs, which were presented at the 2014 American College of Veterinary Internal Medicine (AVCIM) Forum.
Aratana is proud to call the Kansas City our home. Known as America’s Animal Health Corridor, Kansas City is the global leader for animal health and nutrition research, innovation and production.
Veterinarians stand at both the front line of medicine and the fore front of medical knowledge. Aratana Therapeutics will be at a number of veterinary conferences in the coming months to meet veterinarians interested in learning about the scientific advances we want to bring to pet health.
Aratana Therapeutics is sponsoring two nationwide clinical trials.
June 27, 2013, Aratana filed its initial public offering, validating our unique model and approach to bringing advances in human medical science to pets.
The Company will provide an overview of its business at the Jefferies Global Healthcare Conference and the William Blair Annual Growth Stock Conference.
Aratana Therapeutics – a new kind of animal health company – made their veterinary symposium debut at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum.